Spero Therapeutics Inc
Company Profile
Business description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Contact
675 Massachusetts Avenue
14th Floor
CambridgeMA02139
USAT: +1 857 242-1600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,770.70 | 0.40 | -0.00% |
| CAC 40 | 7,683.73 | 58.51 | -0.76% |
| DAX 40 | 23,434.65 | 264.47 | -1.12% |
| Dow JONES (US) | 42,215.80 | 299.29 | -0.70% |
| FTSE 100 | 8,834.03 | 41.19 | -0.46% |
| HKSE | 23,686.49 | 293.81 | -1.23% |
| NASDAQ | 19,521.09 | 180.12 | -0.91% |
| Nikkei 225 | 38,771.93 | 235.19 | 0.61% |
| NZX 50 Index | 12,608.28 | 31.07 | -0.25% |
| S&P 500 | 5,982.72 | 50.39 | -0.84% |
| S&P/ASX 200 | 8,544.50 | 3.20 | 0.04% |
| SSE Composite Index | 3,380.47 | 6.94 | -0.20% |